ABL1 is an inclusion eligibility criterion in 75 clinical trials for myelodysplastic syndromes, of which 44 are open and 31 are closed. Of the trials that contain ABL1 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 24 are phase 1 (11 open), 12 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (0 open) [3].

ABL2 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain ABL2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

AFF1 is an inclusion eligibility criterion in 58 clinical trials for myelodysplastic syndromes, of which 35 are open and 23 are closed. Of the trials that contain AFF1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 23 are phase 1 (12 open), 6 are phase 1/phase 2 (5 open), 24 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 25 clinical trials for myelodysplastic syndromes, of which 21 are open and 4 are closed. Of the trials that contain ASXL1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (4 open), 6 are phase 1/phase 2 (6 open), 12 are phase 2 (10 open), and 1 is phase 2/phase 3 (0 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ATM status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

BCOR is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain BCOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 75 clinical trials for myelodysplastic syndromes, of which 44 are open and 31 are closed. Of the trials that contain BCR status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 24 are phase 1 (11 open), 12 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (0 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 18 clinical trials for myelodysplastic syndromes, of which 9 are open and 9 are closed. Of the trials that contain CBFB status and myelodysplastic syndromes as inclusion criteria, 10 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

CBL is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain CBL status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CREBBP is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

CRLF2 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CRLF2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

DEK is an inclusion eligibility criterion in 66 clinical trials for myelodysplastic syndromes, of which 40 are open and 26 are closed. Of the trials that contain DEK status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 22 are phase 1 (11 open), 9 are phase 1/phase 2 (8 open), 29 are phase 2 (18 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

DNMT3A is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndromes, of which 3 are open and 1 is closed. Of the trials that contain DNMT3A status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 49 clinical trials for myelodysplastic syndromes, of which 27 are open and 22 are closed. Of the trials that contain ELL status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), 18 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

EPOR is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain EPOR status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

ETV6 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain EZH2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR3 is an inclusion eligibility criterion in 6 clinical trials for myelodysplastic syndromes, of which 5 are open and 1 is closed. Of the trials that contain FGFR3 status and myelodysplastic syndromes as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (3 open) [3].

FGFR4 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR4 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

FLT3 is an inclusion eligibility criterion in 87 clinical trials for myelodysplastic syndromes, of which 51 are open and 36 are closed. Of the trials that contain FLT3 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 25 are phase 1 (12 open), 20 are phase 1/phase 2 (15 open), 35 are phase 2 (21 open), 1 is phase 2/phase 3 (0 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain HRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

IDH1 is an inclusion eligibility criterion in 9 clinical trials for myelodysplastic syndromes, of which 8 are open and 1 is closed. Of the trials that contain IDH1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [3].

IDH2 is an inclusion eligibility criterion in 8 clinical trials for myelodysplastic syndromes, of which 8 are open and 0 are closed. Of the trials that contain IDH2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].

IGH is an inclusion eligibility criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain IGH status and myelodysplastic syndromes as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

IKZF1 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and myelodysplastic syndromes as inclusion criteria, 3 are phase 2 (1 open) [3].

IL7R is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain IL7R status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

JAK1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain JAK1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

JAK2 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndromes, of which 3 are open and 1 is closed. Of the trials that contain JAK2 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), and 2 are phase 2 (2 open) [3].

JAK3 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain JAK3 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 20 clinical trials for myelodysplastic syndromes, of which 11 are open and 9 are closed. Of the trials that contain KIT status and myelodysplastic syndromes as inclusion criteria, 10 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (4 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

KMT2A is an inclusion eligibility criterion in 76 clinical trials for myelodysplastic syndromes, of which 47 are open and 29 are closed. Of the trials that contain KMT2A status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 26 are phase 1 (14 open), 11 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

KRAS is an inclusion eligibility criterion in 9 clinical trials for myelodysplastic syndromes, of which 6 are open and 3 are closed. Of the trials that contain KRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].

LYN is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain LYN status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

MAF is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain MAF status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

MAFB is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 163 clinical trials for myelodysplastic syndromes, of which 117 are open and 46 are closed. Of the trials that contain MECOM status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 64 are phase 1 (45 open), 29 are phase 1/phase 2 (23 open), 51 are phase 2 (35 open), 2 are phase 2/phase 3 (1 open), 12 are phase 3 (10 open), and 3 are no phase specified (2 open) [3].

MLF1 is an inclusion eligibility criterion in 115 clinical trials for myelodysplastic syndromes, of which 86 are open and 29 are closed. Of the trials that contain MLF1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 47 are phase 1 (34 open), 22 are phase 1/phase 2 (17 open), 30 are phase 2 (23 open), 2 are phase 2/phase 3 (1 open), 11 are phase 3 (9 open), and 2 are no phase specified (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 50 clinical trials for myelodysplastic syndromes, of which 27 are open and 23 are closed. Of the trials that contain MLLT1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), 19 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 49 clinical trials for myelodysplastic syndromes, of which 27 are open and 22 are closed. Of the trials that contain MLLT10 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), 18 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 55 clinical trials for myelodysplastic syndromes, of which 30 are open and 25 are closed. Of the trials that contain MLLT3 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 24 are phase 1 (12 open), 6 are phase 1/phase 2 (5 open), 20 are phase 2 (11 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 51 clinical trials for myelodysplastic syndromes, of which 28 are open and 23 are closed. Of the trials that contain MLLT4 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 7 are phase 1/phase 2 (6 open), 19 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain MYC status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 18 clinical trials for myelodysplastic syndromes, of which 9 are open and 9 are closed. Of the trials that contain MYH11 status and myelodysplastic syndromes as inclusion criteria, 10 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

NF1 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain NF1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

NPM1 is an inclusion eligibility criterion in 122 clinical trials for myelodysplastic syndromes, of which 90 are open and 32 are closed. Of the trials that contain NPM1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 50 are phase 1 (35 open), 23 are phase 1/phase 2 (18 open), 33 are phase 2 (25 open), 2 are phase 2/phase 3 (1 open), 11 are phase 3 (9 open), and 2 are no phase specified (2 open) [3].

NRAS is an inclusion eligibility criterion in 11 clinical trials for myelodysplastic syndromes, of which 7 are open and 4 are closed. Of the trials that contain NRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open) [3].

NRIP3 is an inclusion eligibility criterion in 49 clinical trials for myelodysplastic syndromes, of which 27 are open and 22 are closed. Of the trials that contain NRIP3 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), 18 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

NUP214 is an inclusion eligibility criterion in 66 clinical trials for myelodysplastic syndromes, of which 40 are open and 26 are closed. Of the trials that contain NUP214 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 22 are phase 1 (11 open), 9 are phase 1/phase 2 (8 open), 29 are phase 2 (18 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 28 clinical trials for myelodysplastic syndromes, of which 19 are open and 9 are closed. Of the trials that contain PBX1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 15 are phase 2 (10 open), and 1 is phase 3 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PDGFRB is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

PDS5B is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PDS5B status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PML is an inclusion eligibility criterion in 6 clinical trials for myelodysplastic syndromes, of which 3 are open and 3 are closed. Of the trials that contain PML status and myelodysplastic syndromes as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 2 are open and 1 is closed. Of the trials that contain PTPN11 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

RAD21 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RAD21 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

RARA is an inclusion eligibility criterion in 6 clinical trials for myelodysplastic syndromes, of which 3 are open and 3 are closed. Of the trials that contain RARA status and myelodysplastic syndromes as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

RIT1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 162 clinical trials for myelodysplastic syndromes, of which 116 are open and 46 are closed. Of the trials that contain RPN1 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 64 are phase 1 (45 open), 29 are phase 1/phase 2 (23 open), 50 are phase 2 (34 open), 2 are phase 2/phase 3 (1 open), 12 are phase 3 (10 open), and 3 are no phase specified (2 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 45 clinical trials for myelodysplastic syndromes, of which 32 are open and 13 are closed. Of the trials that contain RUNX1 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 14 are phase 1 (8 open), 10 are phase 1/phase 2 (10 open), 17 are phase 2 (12 open), 1 is phase 2/phase 3 (0 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 20 clinical trials for myelodysplastic syndromes, of which 11 are open and 9 are closed. Of the trials that contain RUNX1T1 status and myelodysplastic syndromes as inclusion criteria, 10 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

SETBP1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain SETBP1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

SF3B1 is an inclusion eligibility criterion in 6 clinical trials for myelodysplastic syndromes, of which 6 are open and 0 are closed. Of the trials that contain SF3B1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].

SH2B3 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain SH2B3 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

SMC1A is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains SMC1A status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

SMC3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains SMC3 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains SRC status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

SRSF2 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain SRSF2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain STAG2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 28 clinical trials for myelodysplastic syndromes, of which 19 are open and 9 are closed. Of the trials that contain TCF3 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 15 are phase 2 (10 open), and 1 is phase 3 (1 open) [3].

TET2 is an inclusion eligibility criterion in 5 clinical trials for myelodysplastic syndromes, of which 4 are open and 1 is closed. Of the trials that contain TET2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].

TP53 is an inclusion eligibility criterion in 74 clinical trials for myelodysplastic syndromes, of which 48 are open and 26 are closed. Of the trials that contain TP53 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 26 are phase 1 (14 open), 13 are phase 1/phase 2 (11 open), 28 are phase 2 (19 open), 1 is phase 2/phase 3 (0 open), 3 are phase 3 (3 open), and 1 is no phase specified (0 open) [3].

TRA is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TRA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TRB is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TRB status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TRD is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TRD status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TRG is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TRG status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [3].

TYK2 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain TYK2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [3].

U2AF1 is an inclusion eligibility criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain U2AF1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

U2AF2 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains U2AF2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

WHSC1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [3].

ZRSR1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ZRSR1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ZRSR2 is an inclusion eligibility criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain ZRSR2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].